Compare Amgen, Inc. (AMGN) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Lennar Corporation — how do they compare? Amgen, Inc. trades at $356.72 (market cap $196.12B), while Lennar Corporation trades at $83.98 (market cap $20.25B). The key difference: Amgen, Inc. is far larger — about 9.7× Lennar Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | LEN | |
|---|---|---|
Market Cap | $196.12B | $20.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $142.40 |
52-Week Low | $271.18 | $82.30 |
Enterprise Value | $241.41B | $24.13B |
Dividend Yield | 2.77% | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Lennar Corporation (LEN) trades at $84.27, down 0.09% on the day, with the stock showing bearish technical signals despite trading near analyst consensus targets. The homebuilder faces margin pressure with net income declining from $4.6B in 2022 to $2.1B in 2025, though valuation metrics appear attractive with P/E of 13.2 and P/B of 0.9. Recent earnings have consistently missed expectations, with Q2 2026 results showing mixed performance amid challenging housing market conditions.
LEN presents a value opportunity with discounted valuations but faces significant headwinds from declining profitability and housing market volatility. The stock's outlook hinges on execution amid affordability pressures, with analyst consensus leaning bullish (46% buy ratings) but technical indicators suggesting caution. Key risks include ongoing margin compression and macroeconomic sensitivity to interest rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
